GNT Biotech Advances GNTbm-38 with IND Filings in US & China by 2026

日期2025-09-18

Dr. Chia-Nan Chen, Chairman and President of GNTbm (Photo by Linna Li)

A-
A+

加入收藏

GNT Biotech & Medicals Corporation (GNTbm) is advancing GNTbm-38, a next-generation oral immuno-regulatory drug, with IND filings planned in the US & China by early 2026.

Investment Highlights

Global IP Strength: 38 invention patents secured worldwide.
Pipeline Milestone: GNTbm-38 demonstrated 100% ORR in preclinical models; first indication set for R/R PTCL (orphan drug strategy).
Commercial Potential: Expansion planned into DLBCL and colorectal cancer, positioning for global licensing and partnerships.

With its dual mechanism design (HDAC2 inhibition + immune activation), GNTbm-38 aims to reshape the tumor microenvironment and unlock new value in immuno-oncology.

Read More, Learn More: https://news.gbimonthly.com/tw/article/show.php?num=80336

Follow us for more news and Taiwan biotech ecosystem updates!